Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
EAST NORRITON, Pa., Oct. 27 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, reviewed pipeline progress at its first Analyst and Investor Meeting which was held today in New York City. The event featured updates and discussions of milestones and key data for the Company's Neo-Urinary Conduit™ and Neo-Kidney Augment™ programs. An audio archive of the event and presentation materials will be available at the Investors section of the Tengion website at www.tengion.com.
Neo-Urinary Conduit Bladder Cancer Trial – Clinical Update
The Company's Neo-Urinary Conduit was recently implanted in the first patient as part of the ongoing initial clinical trial evaluating the Company's lead product candidate in bladder cancer patients requiring a urinary diversion following bladder removal. The patient is being treated at the University of Chicago Medical Center by the principal investigator at the site for this study, Gary D. Steinberg, M.D., Professor of Surgery and Director, Urologic Oncology. The trial is also being conducted at The Johns Hopkins Hospital in Baltimore, Maryland.
"We are very pleased that investigators have identified, enrolled, biopsied, and implanted the first patient with our regenerative Neo-Urinary Conduit," stated Sunita Sheth, M.D., vice president and chief medical officer. "With the first implant completed and two sites actively screening patients, we and our investigators are optimistic that the pace of enrollment will accelerate."
Neo-Kidney Augment Program Update
The Neo-Kidney Augment is the Company's lead preclinical program and is intended to prevent or delay the need for dialysis or kidney transplant by increasing functional renal mass in patients with advanced chronic renal disease, a significant